GlassScriptPhysician profile
Mae D Johnson
NPI 1912905464
$6,084.47
in general payments reported to CMS, 2019-2025
43 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,480 · 2023: $1,225 · 2024: $1,051 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,551.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.77 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.46 | 2021-2025 | Jardiance, Ofev |
| Abbvie INC. | $495.63 | 2021-2025 | |
| Pfizer INC. | $431.39 | 2021-2025 | |
| Amgen INC. | $388.36 | 2021-2025 | Repatha, Otezla, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $332.15 | 2021-2025 | |
| Abbott Laboratories | $320.56 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $298.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $236.53 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $224.04 | 2021-2023 | |
| Lilly USA, LLC | $203.80 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $193.44 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.59 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $124.95 | 2022 | |
| Astellas Pharma US INC | $106.73 | 2021-2024 | Veozah, Myrbetriq |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $87.12 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Eisai INC. | $83.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.06 | 2022 | |
| Sumitomo Pharma America, INC. | $76.36 | 2023-2025 | Gemtesa |
| Medtronic, INC. | $75.60 | 2023-2025 | Intellis Adaptivestim, Minimed 780g |
| Esperion Therapeutics, INC. | $72.43 | 2021 | |
| Xeris Pharmaceuticals, INC. | $71.45 | 2022-2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $67.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.94 | 2021-2025 | Capvaxive, Gardasil 9 |
| Shield Therapeutics INC | $63.88 | 2022-2024 | Accrufer |
| Phathom Pharmaceuticals, INC. | $56.30 | 2025 | Voquezna |
| Boston Scientific Corporation | $47.60 | 2025 | Watchman Access System |
| Daiichi Sankyo INC. | $46.54 | 2023 | Injectafer |
| Indivior INC. | $42.62 | 2024-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.02 | 2024-2025 | Caplyta |
| Seqirus USA INC | $34.46 | 2025 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $33.65 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $27.42 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $26.71 | 2022 | |
| Sanofi Pasteur INC. | $22.75 | 2025 | |
| Lundbeck LLC | $20.79 | 2025 | Rexulti |
| Amarin Pharma, INC. | $18.43 | 2021 | |
| Convatec INC. | $14.76 | 2021 | |
| Ethicon US, LLC | $14.53 | 2021 | |
| Biogen, INC. | $14.36 | 2021 | |
| Exact Sciences Corporation | $13.67 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $13.64 | 2022 | |
| Almatica Pharma LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mae Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.